Behind Global Blood and Novartis, Bluebird leads a pack of biotechs wanting a slice of the sickle cell disease market.
With data from a head-to-head trial against Cosentyx due soon, UCB’s bimekizumab seeks to enter a crowded psoriasis market.
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
One trial of Pfizer’s drug in early breast cancer has been stopped, and expectations dim for another.
June will be hectic for the US regulator, with many approval decisions due, including one for subcutaneous Arzerra in multiple sclerosis and Tazverik in follicular…
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.
So far so good, as much of pharma shrugs off the full-year impact of Covid-19.
The smoking-cessation drug, reformulated for nasal delivery, could be launched for dry eye, Oyster Point hopes.